Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
Tumor-derived endothelial cells (TDECs)
Cells
N/A nM (reported value)
IMC Medium: 1X M9 Salts (40 mM Na2HPO4, 20 mM KH2PO4, 8.5 mM NaCl, 20 mM NH4Cl, pH 7.4), 0.2% casamino acids, 0.5% glucose, 1 mM MgCl2.
Incubation/Wash solution: IMC medium containing 10% fetal calf serum (FCS) and 1% a-methyl mannoside. 4°C NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding. Binds to TDECs.
Counter-SELEXed against Matrigel invading cells (MAGIC) and minimal binding to NIH3T3 cells.
Tumor-derived endothelial cells (PepMW3) (ID# 383)
Incubation/Wash solution: IMC medium containing 10% fetal calf serum (FCS) and 1% a-methyl mannoside. 4°C NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding. Binds to TDECs.
Counter-SELEXed against Matrigel invading cells (MAGIC) and minimal binding to NIH3T3 cells.
5'CysGlyGlyArgArgLeuGlyGlyCys3'
9
960.21 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
C K Brown et al. A novel approach for the identificaiton of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol. 7(2000): 743-749.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.